dc.contributor.author | Jacob, Jorge | |
dc.contributor.author | Biering-Sørensen, Tor | |
dc.contributor.author | Holger Ehlers, Lars | |
dc.contributor.author | Edwards, Christina Hansen | |
dc.contributor.author | Mohn, Kristin Greve-Isdahl | |
dc.contributor.author | Nilsson, Anna | |
dc.contributor.author | Hjelmgren, Jonas | |
dc.contributor.author | Ma, Wenkang | |
dc.contributor.author | Sharma, Yuvraj | |
dc.contributor.author | Ciglia, Emanuele | |
dc.contributor.author | Mould-Quevedo, Joaquin | |
dc.date.accessioned | 2023-09-14T11:48:08Z | |
dc.date.available | 2023-09-14T11:48:08Z | |
dc.date.created | 2023-05-12T14:24:18Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 2076-393X | |
dc.identifier.uri | https://hdl.handle.net/11250/3089459 | |
dc.description.abstract | Individuals aged 65 years and above are at increased risk of complications and death from influenza compared with any other age group. Enhanced vaccines, as the MF59®-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (HD-QIV), provide increased protection for older adults in comparison to the traditional standard-dose quadrivalent influenza vaccines (SD-QIV). This study aimed to assess the cost-effectiveness of aQIV compared to SD-QIV and HD-QIV in Denmark, Norway, and Sweden for adults aged ≥65 years. A static decision tree model was used to evaluate costs and outcomes of different vaccination strategies from healthcare payer and societal perspectives. This model projects that compared to SD-QIV, vaccination with aQIV could prevent a combined total of 18,772 symptomatic influenza infections, 925 hospitalizations, and 161 deaths in one influenza season across the three countries. From a healthcare payer perspective, the incremental costs per quality adjusted life year (QALY) gained with aQIV versus SD-QIV were EUR 10,170/QALY in Denmark, EUR 12,515/QALY in Norway, and EUR 9894/QALY in Sweden. The aQIV was cost saving compared with HD-QIV. This study found that introducing aQIV to the entire population aged ≥65 years may contribute to reducing the disease and economic burden associated with influenza in these countries. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Cost-Effectiveness of Vaccination of Older Adults with an MF59®-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2023 The Author(s) | en_US |
dc.source.articlenumber | 753 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/vaccines11040753 | |
dc.identifier.cristin | 2147198 | |
dc.source.journal | Vaccines | en_US |
dc.identifier.citation | Vaccines. 2023, 11 (4), 753. | en_US |
dc.source.volume | 11 | en_US |
dc.source.issue | 4 | en_US |